NCT03409016: Biomarkers of Immune-Related Toxicity

NCT03409016
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be starting a new treatment regimen of Yervoy/ipilimumab, Opdivo/nivolumab, Keytruda/pembrolizumab or Tecentriq/atezolizumab as a single agent or in combination
Exclusions: Patients with prior immune checkpoint inhibitor therapy with anti-CTLA4, anti-PD1 or anti-PD-L1 targeting agent (e.g. Keytruda/pembrolizumab or Tecentriq/atezolizumab)
https://ClinicalTrials.gov/show/NCT03409016

Comments are closed.

Up ↑